Moberg Pharma — Capital/Financing Update 2016

Feb 23, 2016

Moberg Pharma publishes bond prospectus and applies for listing of its bond loan on Nasdaq Stockholm

STOCKHOLM, February 23rd 2016. Moberg Pharma AB (publ) ("Moberg Pharma" or "the company", OMX: MOB) publishes a bond prospectus and applies for listing on Nasdaq Stockholm of its bond loan.

On January 25th 2016, Moberg Pharma announced that the company has issued a senior unsecured bond loan in the amount of SEK 300 million within a total framework amount of SEK 600 million. The bond loan will mature on January 29th 2021 and carries an annual interest rate of STIBOR (3 months) + 6.00 percentage points.

The company has applied for listing of the bon loan on Nasdaq Stockholm and the first day of trading is expected to be on February 25th 2016. In view of the listing, the company has prepared a prospectus that has been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The prospectus is available on the company's website www.mobergpharma.se and on the Swedish Financial Supervisory Authority's website www.fi.se.

For additional information contact:

Peter Wolpert, CEO, Telephone: +46 707 35 71 35, E-mail: peter.wolpert@mobergpharma.se Anna Ljung, CFO, Telephone: +46 707 66 60 30, E-mail: anna.ljung@mobergpharma.se

About this information

Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 11.00 am (CET) on February 23rd 2016.

About Moberg Pharma AB (publ)

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company's portfolio includes the OTC brands Kerasal® , Kerasal Nail® , Balmex® , Domeboro® , Jointflex® , Vanquish® , and Fergon® . Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada and several EU markets and is currently being launched in Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focuses on innovative drug delivery of proven compounds and include two phase II assets, MOB-015 (onychomycosis) and BUPI (oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB). For further information, please visit: www.mobergpharma.com.